Mesenchymal Stem Cell therapy in COVID19

Phase 1

• Conditions: COVID-19 Disease.; COVID-19 Disease; U07.02

• Registration Number: IRCT20200325046860N2
• Lead Sponsor: Bagheiat-allah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Male or female, aged at 18 years (including) -70 years old
Laboratory confirmation of 2019-nCoV infection by reverse-transcription polymerase chain reaction (RT-PCR) from any diagnostic sampling source
Pneumonia that is judged by chest radiograph or computed tomography.
Resp rate> 30, o2 sat < 93%,

Exclusion Criteria

Pregnancy, lactation
Patients with malignant tumor, other serious systemic diseases and psychosis
Patients who are participating in other clinical trials;
Inability to provide informed consent
Co-Infection of HIV, tuberculosis, influenza virus

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Respiratory function of patients. Timepoint: Every 24 hours after MSC infusion. Method of measurement: Clinical, lab test , CT scan.